KAPA Diagnostics Kits

The Centers for Disease Control and Prevention (CDC) intends to award a fixed-price contract on a sole source basis to Roche Diagnostics for KAPA Diagnostics Kits. This is the only known Vendor who is able to develop high quality reagents used in next generation sequencing (NGS) for the Illumina platform. Virus Special Pathogens Branch has Illumina iSeq, MiniSeq, and MiSeq sequencing instruments to perform sequencing of virus genomes and host response to infection and antiviral treatments. VSPB requires Roche Diagnostic reagents in the preparation of libraries used in the NGS protocols developed by VSPB and specific for VSPB’s hemorrhagic fever viruses. The VSPB protocols have been in use for over 6 years and optimized to use the Roche KAPA sequencing reagents. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR Part FAR 13.106–1 (b) and 10 U.S.C. 2304 (c) (1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This Notice of Intent is not a request for competitive quotations; however, all quotations/responses received within six (6) calendar days of the issuance of this notice will be considered by the Government. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to the Contract Specialist, Robin C. Meyer, at [email protected] by 9:45pm ET, Monday, 29 August 2022.